Glimepirid 1 A Pharma

Glimepirid 1 A Pharma is a product that contains the active ingredient glimepiride, supplied as an oral tablet for the EU market. It belongs to the sulfonylurea class of antidiabetic agents and is available by prescription. The medication works by stimulating insulin release from pancreatic beta‑cells, helping to lower blood glucose in patients with type 2 diabetes mellitus. Glimepirid 1 A Pharma complies with EU guidelines and is used for glycemic control.

Glimepirid 1 A Pharma is indicated for the management of elevated blood glucose in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

- Used as monotherapy when diet, exercise, and other oral agents are insufficient. - Combined with metformin or other antidiabetic agents to improve glycemic control. - May be prescribed when patients have stable renal function and no contraindications to sulfonylureas. - Helpful in patients who require a once‑daily oral medication. - Considered for individuals who need additional post‑prandial glucose reduction.

The safety profile of glimepiride includes a range of observed effects that vary in frequency and severity.

Common: - Low blood sugar (hypoglycemia), especially if meals are missed. - Weight gain due to increased insulin activity. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic reactions such as skin rash, swelling, or anaphylaxis.

Before initiating Glimepirid 1 A Pharma, clinicians should evaluate several precautionary factors to ensure safe use.

- Assess renal and hepatic function; dose adjustments may be needed in impairment. - Review patient history for prior sulfonylurea hypersensitivity or severe hypoglycemia. - Use caution in elderly patients who are more prone to low blood sugar. - Avoid use during pregnancy and breastfeeding unless benefits outweigh risks. - Monitor blood glucose regularly after dose changes. - Consider cardiovascular status, as sulfonylureas may affect ischemic preconditioning.

Glimepirid 1 A Pharma can interact with other medicines, altering its effectiveness or increasing adverse effects.

Avoid: - Concomitant use with other sulfonylureas or insulin may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) can raise glimepiride levels.

Use with caution: - Beta‑blockers may mask hypoglycemia symptoms. - Thiazide diuretics can increase blood glucose variability. - NSAIDs may affect renal function, influencing drug clearance. - Antidepressants such as SSRIs may alter glycemic control.